塞特梅拉诺提德:一种梅拉诺科尔-4受体激活剂,用于治疗由于下丘脑功能障碍导致的严重肥胖症
Sulmaaz Qamar1,2,3, Ritwika Mallik1,2,3, Janine Makaronidis1,2,3,4
1Centre for Obesity Research, Rayne Institute, Department of Medicine, University College London, London, UK.
TouchREVIEWS in endocrinology
|November 11, 2024
概括
塞特梅拉诺提德通过准莱普-梅拉诺科丁通路,为单一性肥胖提供了突破性的解决方案. 这种向疗法对严重的遗传肥胖症和相关疾病具有前景.
科学领域:
- 内分泌学 在内分泌学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖是一个复杂的全球流行病,受遗传学和环境的影响.
- 单一性肥胖症是一种严重的早期发病形式,由影响下丘脑体重调节的遗传缺陷引起.
- 瘦素-黑色素皮质素通路对于体重控制至关重要,其功能障碍是单一性肥胖症的基础.
研究的目的:
- 审查setmelanotide在治疗单一性肥胖症中的疗效和安全性.
- 在临床试验中探索setmelanotide的作用机制和结果.
- 讨论setmelanotide在其他遗传肥胖形式中的潜力.
主要方法:
- 对setmelanotide的临床试验数据的审查.
- 对setmelanotide的药理概况和作用机制的分析.
- 探索遗传肥胖的病理生理学和治疗目标.
主要成果:
- 在POMC和PCSK1缺陷中,Setmelanotide显著减肥并改善了代谢参数.
- 该药物向黑色皮质素-4受体,有效地恢复通路功能.
- 目前正在进行的研究正在调查setmelanotide在其他罕见的遗传肥胖综合征中的实用性.
结论:
- 塞特梅拉诺提德是一种有效的向治疗,用于特定的遗传形式的肥胖.
- 这种治疗方法在治疗严重,复杂的遗传肥胖症方面取得了重大进展.
- 需要进一步的研究来扩大setmelanotide的应用范围到更广泛的遗传肥胖状况.
相关概念视频
01:30Regulation of Food Intake
193
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
193
01:24Glucagon-like Receptor Agonists
300
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
300
01:23Antidepressant Drugs: MAOIs and Other Agents
195
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
195
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
146
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
146
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
212
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
212